Atopic Dermatitis

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Silverberg discussers 16-week data for rezpegaldesleukin in atopic dermatitis from the phase 2b REZOLVE-AD trial.

Amlitelimab shows promise as a safe and effective treatment for moderate-to-severe atopic dermatitis, with sustained benefits post-treatment.

This interview segment at the 2025 SDPA Conference highlights additional insights by Friedman on the management and diagnosis of chronic hand eczema, or CHE.

In an interview conducted at the 2025 SDPA Conference, Friedman provided several insights into management and diagnosis of chronic hand eczema, or CHE.

At SDPA 2025, Candrice Heath, MD, said many clinicians remain unaware of baby perfume traditions that may contribute to persistent symptoms in patients of color.

At SDPA 2025, Candrice Heath, MD, presented on what you can do in your clinic to bridge the gap in pediatric atopic dermatitis among children with darker skin tones.

Rezpegaldesleukin showed significant efficacy in improving EASI scores in moderate-to-severe atopic dermatitis patients.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

This Q&A interview with Lisa Swanson, MD, features a discussion of the highlights of Swanson’s talk at RAD 2025 regarding pediatric atopic dermatitis.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

In this Q&A interview at RAD 2025, Tiffany Mayo, MD, highlights the biggest takeaways from her talk on complex cases in atopic dermatitis and hair loss.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.